Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season

NCT00316264 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT00316264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00316264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
February 28, 2007
Enrollment
260 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lung disease and <= 24 months of age or, premature with gestational age <=35 weeks and <=6 months of age, respiratory syncytial virus infections